✦ LIBER ✦

Role of glutathione in cisplatin resistance in osteosarcoma cell lines

✍ Scribed by S. Komiya; M. C. Gobhardt; D. C. Mangham; A. Inoue

Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 780 KB
Volume: 16
Category: Article
ISSN: 0736-0266
DOI: 10.1002/jor.1100160104

No coin nor oath required. For personal study only.

✦ Synopsis

This study was designed to examine whether and how glutathione and catalase increase the resistance of osteosarcoma cells to the toxicity of cisplatin. Eight osteosarcoma cell lines were exposed to varying concentrations of cisplatin, and a [3H]thymidine incorporation study then estimated their drug sensitivity. Cells were pretreated with aminotriazole and buthionine sulfoximine to depress catalase and glutathione activities and then entered into the same protocol to assess their sensitivity to cisplatin. Intracytoplasmic levels of catalase and glutathione were measured before and after the treatments. Cisplatin-glutathione conjugates were created to examine how glutathione might depress the toxicity of cisplatin. Although the cell lines differed in the magnitude of their response to cisplatin, there was a statistical correlation between intrinsic glutathione content and cisplatin resistance. Pretreatment with aminotriazole reduced catalase activity by 84% but did not change the sensitivity to cisplatin. Depletion of glutathione activity by 70% increased the sensitivity of the cells to the cytotoxicity of cisplatin. In addition, cisplatin was detoxified following conjugation with glutathione. The increased sensitization to cisplatin toxicity caused by the depletion of glutathione and cisplatin detoxification after the in vitro reaction of glutathione to cisplatin indicated that the formation of the glutathione-cisplatin conjugate was an important mechanism in the cellular resistance to cisplatin. These data also demonstrated that catalase activity did not contribute to resistance to cisplatin and suggested that H2O2-induced oxidative stress did not significantly contribute to the cytotoxicity of cisplatin in osteosarcoma cells.

📜 SIMILAR VOLUMES

Platinum agents in the treatment of oste

Platinum agents in the treatment of osteosarcoma: Efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines

✍ Robson, H. ;Meyer, S. ;Shalet, S.M. ;Anderson, E. ;Roberts, S. ;Eden, O.B. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

## Abstract ## Background Cisplatin (cDDP), when used either alone or, more often, in combination with other agents, especially adriamycin, achieves a high response rate in osteosarcoma. Its use, however, is limited by severe nephro‐ and neuro‐toxicity. Second generation platinum compounds, most n

Contribution of glutathione and glutathi

Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines

✍ Gi-Ming Lai; Jeffrey A. Moscow; Manuel G. Alvarez; Antonio T. Fojo; Susan E. Bat 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 988 KB

Four human colon cancer cell lines (SW620, LS 180, DLD-I, and HCT-15) and sub-lines isolated in vitro by selection with Adriamycin were studied for reversal of intrinsic and acquired Adriamycin resistance, using buthionine sulfoximine (BSO) to deplete cellular glutathione alone and in combination wi

Identification of genomic changes associ

Identification of genomic changes associated with cisplatin resistance in testicular germ cell tumor cell lines

✍ Elodie E. Noel; Jackie Perry; Tracy Chaplin; Xueying Mao; Jean-Baptiste Cazier; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Since the introduction of cisplatin into the clinic, the treatment of patients with a variety of solid tumors including testicular germ cell tumors, ovarian and lung cancers, has dramatically improved. One of the main causes for therapeutic failure in these malignancies is the developme

Increased accumulation of p53 protein in

Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines

✍ Robert Brown; Carol Clugston; Angela Edlin; Paul Vasey; Stanley B. Kaye; Philip 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 942 KB

## Abstract We have examined p53 protein levels in cell lines selected for resistance to the chemotherapeutic drug __cis__‐diamminedichloroplatinum (II), cisplatin. The majority of the independent cisplatin‐resistant clones isolated by a single selection with cisplatin from the ovarian tumour cell

Codominance of cisplatin resistance in s

Codominance of cisplatin resistance in somatic cell hybrids

✍ Yu-Lan Mary Ying; Ding-Wu Shen; Xing-Jie Liang; Michael M. Gottesman 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB

## Abstract Intrinsic or acquired resistance to cisplatin in cancer cells remains a major obstacle to successful chemotherapy. The clinically relevant genetic and molecular mechanisms of resistance have not yet been identified. Cisplatin‐resistant (CP‐r) human KB epidermoid carcinoma cell lines (He

Mechanism of resistance to cisplatin in

Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53

✍ Faina Vikhanskaya; Luana Clerico; Monica Valenti; Maria S. Stanzione; Massimo Br 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 99 KB 👁 2 views

A possible novel mechanism of cross-resistance to cisplatin (CDDP) in the doxorubicin-resistant ovarian-cancer cell line A2780-DX3, which displays atypical multidrug resistance, is presented. A2780-DX3 is found to be more resistant than the parental line A2780 in terms of CDDP-induced cytotoxicity a